Search hospitals > Ontario > TORONTO

Mount Sinai Hospital

Claim this profile
TORONTO, Ontario M5G 1X5
Global Leader in Bleeding
Global Leader in Postpartum Hemorrhage
Conducts research for Crohn's Disease
Conducts research for Breast Cancer
Conducts research for Pain
439 reported clinical trials
43 medical researchers
Photo of Mount Sinai Hospital in TORONTOPhoto of Mount Sinai Hospital in TORONTOPhoto of Mount Sinai Hospital in TORONTO

Summary

Mount Sinai Hospital is a medical facility located in TORONTO, Ontario. This center is recognized for care of Bleeding, Postpartum Hemorrhage, Crohn's Disease, Breast Cancer, Pain and other specialties. Mount Sinai Hospital is involved with conducting 439 clinical trials across 461 conditions. There are 43 research doctors associated with this hospital, such as Mrinalini Balki, MD, Jose Carvalho, MD, Yehoshua Gleicher, MD, MSc, and Christian Pagnoux, MD, MS, MPH.

Top PIs

Clinical Trials running at Mount Sinai Hospital

Postpartum Hemorrhage
Labor Pain
Bronchopulmonary Dysplasia
Bleeding
Necrotizing Enterocolitis
Breast Cancer
Gastric Cancer
Neonatal Sepsis
Premature Birth
Crohn's Disease
Image of trial facility.

Carbetocin vs Oxytocin

for Postpartum Hemorrhage

The goal of this study is to compare 2 medications that are commonly used to prevent excess uterine bleeding (postpartum hemorrhage, or PPH) following cesarean delivery (CD), oxytocin and carbetocin. Most of the trials evaluating the preventative role of oxytocin and carbetocin after CD have focused on patient with low-risk of PPH. This trial will focus on patients that are at increased risk of PPH, with risk factors such as: multiple gestation (twins, or more multiples), large baby, polyhydramnios (excess amniotic fluid), history of PPH, body mass index greater than 40, diabetes mellitus, hypertension, and placenta previa. The investigators hypothesize that carbetocin would be more effective than an oxytocin regimen in reducing the risk of PPH in patients undergoing CD with any of the biological high-risk factors.
Recruiting1 award N/A
Image of trial facility.

Carbetocin

for Postpartum Hemorrhage

Postpartum hemorrhage (PPH) continues to be an increasing problem globally. Uterotonics play an essential role in the pharmacological management of uterine atony. Carbetocin, a long acting analog of oxytocin has been recommended as a first line uterotonic for PPH prophylaxis at cesarean delivery. Considering many woman have associated comorbidities and are at high risk of PPH, finding alternative pharmacological agents is essential. Calcium is a key factor for myometrial contractions and calcium blood levels can be low at the end of pregnancy. Both hypocalcemia and hypercalcemia could lead to a decrease in myometrial contractions. It is already been demonstrated that in both desensitized and naïve myometrium, normocalcemia provides a better uterine tone compared to hypo and hypercalcemia when oxytocin is given as the first uterotonic drug. Currently, the role of extracelullar calcium in carbetocin- induced contractility is unknown. This will be the first ex vivo study to test the effects of extracellular calcium on oxytocin pretreated and naive myometrium. The results of this study will provide evidence on the use of this safe drug in clinical practice, particularly in women with labour arrest, and provide alternative pharmacological strategies to both prevention and treatment of PPH, thus improving our clinical practice. The investigators hypothesize that extracellular normocalcemia would provide superior carbetocin-mediated contractility in both naive and oxytocin-pretreated myometrium compared with hypercalcemia and hypocalcemia.
Recruiting1 award N/A1 criteria
Image of trial facility.

Oxytocin

for Postpartum Hemorrhage

This study is designed to determine the minimal effective oxytocin maintenance infusion required in labouring women undergoing cesarean delivery to achieve the best effect. Oxytocin is a drug that is routinely used to help the uterus to contract and keep it contracted after delivery. Consequently, it will help to reduce blood loss after delivery. In order to determine the minimal effective dose, the investigators will conduct a dose-finding study. The first patient will receive a set oxytocin infusion. The next patient's infusion dose of oxytocin, will either increase or decrease, depending on how the previous patient responds in terms of uterine tone. If the response is satisfactory with the infusion dose used, the next patient will either receive the same infusion dose or it will be decreased depending on a probability of 1:9. If the response is not satisfactory, then the infusion dose will increase for the next patient. The dose for each patient will be determined based on the results of the uterine contraction of the previous patient. The investigators hypothesize that the ED90 of the oxytocin infusion rate to maintain adequate uterine tone in labouring women with induced or augmented labour undergoing cesarean delivery, following an initial effective bolus dose, would be lower than 0.74 IU/min (44 IU/h), which was found as the ED90 in a previous study, without an initial bolus dose prior to the infusion.
Recruiting1 award N/A

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Mount Sinai Hospital?
Where is Mount Sinai Hospital located?
Who should I call to ask about financial aid or insurance network?
What insurance does Mount Sinai Hospital accept?
What awards or recognition has Mount Sinai Hospital received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security